Status:
UNKNOWN
Cytokine Hemadsorption in Covid 19 Patients With Bacterial Sepsis
Lead Sponsor:
Derince Training and Research Hospital
Conditions:
INTERLEUKIN 6
Eligibility:
All Genders
18-80 years
Brief Summary
In this retrospective study, we aimed to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.
Eligibility Criteria
Inclusion
- COVID-19 patients were the available data of laboratory diagnosis of COVID-19 (a positive throat swab nucleic acid test or positive serum COVID-19 specific antibody test),
- patients with COVID-19 induced sepsis was detection of bacterial agent in blood or tracheal culture
Exclusion
- below 18 aged
- those who did not undergo hemoperfusion
Key Trial Info
Start Date :
June 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 20 2021
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT04920851
Start Date
June 10 2021
End Date
July 20 2021
Last Update
June 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Biruni University
Istanbul, Küçükçekmece, Turkey (Türkiye), 34100